Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Jacobio Pharma Announced its KRAS G12C inhibitor reached the primary endpoint 2024-05-01 08:59
Jacobio Pharma to Present Data of PARP7 Inhibitor and P53 Reactivator at the 2024 AACR Annual Meeting 2024-04-09 19:59
Jacobio Pharma Announces 2023 Annual Results 2024-03-29 08:50
Jacobio Pharma Receives IND Approval for P53 Y220C Activator JAB-30300 in the U.S. 2024-03-01 14:55
Jacobio Announces China CDE Clearance for Phase III Clinical Trial of SHP2 Inhibitor Plus KRAS G12C Inhibitor 2024-02-18 20:50
Jacobio Pharma Presents Data of Glecirasib in Patients with Pancreatic Cancer and Other Solid Tumors at the 2024 ASCO GI 2024-01-20 06:30
Jacobio Pharma Presents Clinical Results of Glecirasib in Combination with JAB-3312 at ESMO 2023-10-22 15:05
Jacobio Pharma Announces 2023 Interim Results 2023-08-30 21:45
Jacobio Pharma Announces Breakthrough Therapy Designation from China CDE for KRAS G12C Inhibitor Glecirasib for the Treatment of Pancreatic Cancer 2023-08-07 20:03
Jacobio Pharma to Present Data of Glecirasib in Combination with JAB-3312 at the 2023 ESMO Conference 2023-07-21 10:19
Jacobio Receives CDE Approval for Glecirasib's Pancreatic Cancer Pivotal Study in China 2023-07-04 21:16
Jacobio Pharma Presents Clinical Results of Glecirasib in Colorectal Cancer 2023-06-29 16:31
Jacobio Pharma Announces 2022 Annual Results 2023-03-22 22:38
Jacobio announces clinical collaboration to evaluate CD73 monoclonal antibody JAB-BX102 in combination with KEYTRUDA® (pembrolizumab) for patients with cancer 2023-03-22 12:36
Jacobio Pharma to Present Data of Three Preclinical Studies at the 2023 AACR Annual Meeting 2023-03-15 10:45
Jacobio Completes First Patient Dosage of Aurora A Inhibitor JAB-2485 in U.S 2023-01-08 14:17
Jacobio's KRAS G12C Inhibitor JAB-21822 was Granted Breakthrough Therapy Designations by China CDE 2022-12-16 08:42
Jacobio's Preclinical Results of KRAS G12C Inhibitor in Combination with SHP2 Inhibitor Will be Presented at the ESMO Asia Congress 2022 2022-12-02 08:30
Jacobio Pharma to Collaborate with Merck on Clinical Trial of JAB-21822 in Combination with Cetuximab 2022-10-13 09:00
Jacobio Receives CDE Approval for KRAS G12C Inhibitor JAB-218822's Phase II Pivotal Study in China 2022-09-06 15:20
1 2